NCT04090398: Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer Spread to the Bones

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Chemotherapy, Radiation Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Bone
Additional Notes: Patients may have metastasis outside of the bone, but they must be asymptomatic and have 5 or less visceral metastasis; Patients with HR+ disease should have progressed on at least one prior line of hormone therapy + a CDK4/6 inhibitor (e.g. Ibrance/palbociclib, Verzenio/abemaciclib, Kisqali/ribociclib) in the metastatic setting
Exclusions: Patients that do NOT have two or more bone metastases; Patients with symptomatic, unstable, untreated brain metastases- see trial for details

Comments are closed.

Up ↑